Evolus Inc

EOLS

Company Profile

  • Business description

    Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

  • Contact

    520 Newport Center Drive
    Suite 1200
    Newport BeachCA92660
    USA

    T: +1 949 284-4555

    E: [email protected]

    https://www.evolus.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    350

Stocks News & Analysis

stocks

Ask the analyst: Where does GYG stand following its US exit?

All roads lead back home for Guzman Y Gomez.
stocks

Chart of the Week: The long term headwinds facing copper shares

The key factors challenging the bull case for copper demand.
stocks

Australia’s oldest REIT undervalued

This REIT remains undervalued as trophy properties shine through.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,930.909.200.10%
CAC 408,452.09114.801.38%
DAX 4025,454.27413.991.65%
Dow JONES (US)52,305.2413.96-0.03%
FTSE 10010,574.3095.960.92%
HKSE23,055.03174.010.76%
NASDAQ26,040.03173.69-0.66%
Nikkei 22568,733.151,741.81-2.47%
NZX 50 Index13,582.1928.31-0.21%
S&P 5007,483.230.000.00%
S&P/ASX 2008,724.5013.900.16%
SSE Composite Index4,028.9083.54-2.03%

Market Movers